| scholarly article | Q13442814 |
| P50 | author | Ann-Lii Cheng | Q38639483 |
| Po-huang Lee | Q42651898 | ||
| P2093 | author name string | Chin-Lun Huang | |
| Hey-Chi Hsu | |||
| Chiun Hsu | |||
| Shiou-Jeng Wang | |||
| P2860 | cites work | Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 |
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Reporting results of cancer treatment | Q29620070 | ||
| C-erbB-2 immunostaining: problems with interpretation | Q37104860 | ||
| Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization | Q38462511 | ||
| HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization | Q38474353 | ||
| Treatment of hepatocellular carcinoma: too many options? | Q40761519 | ||
| Heregulin regulation of Akt/protein kinase B in breast cancer cells | Q40936401 | ||
| Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment | Q46641346 | ||
| Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy | Q59274612 | ||
| Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan. A comparison with resected large HCC | Q70089309 | ||
| Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer | Q71059676 | ||
| Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies | Q72228246 | ||
| Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy | Q72675847 | ||
| Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system | Q73181576 | ||
| Experts debate value of HER2 testing methods | Q73450065 | ||
| Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies | Q73490475 | ||
| NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways | Q77904536 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell growth | Q189159 |
| hepatocellular carcinoma | Q1148337 | ||
| overexpression | Q61643320 | ||
| P304 | page(s) | 415-420 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity | |
| P478 | volume | 94 |
| Q34611637 | A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas |
| Q37738067 | An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients |
| Q47602776 | Analysis of mucin, p53 protein and Ki-67 expressions in gastric differentiated-type intramucosal neoplastic lesions obtained from endoscopic mucosal resection samples: a proposal for a new classification of intramucosal neoplastic lesions based on n |
| Q36519010 | Dysregulation of growth factor signaling in human hepatocellular carcinoma. |
| Q37696540 | Gene expression of growth factors and growth factor receptors for potential targeted therapy of canine hepatocellular carcinoma. |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q37639917 | Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells. |
| Q37349973 | Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer |
| Q37766798 | Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives |
| Q37779804 | Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib |
| Q34433064 | Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. |
| Q35588545 | Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma |
| Q35535968 | Presentation and outcomes of hepatocellular carcinoma patients at a western centre |
| Q58693837 | Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib |
| Q42180761 | TOP2A amplification and overexpression in hepatocellular carcinoma tissues. |
| Q47576870 | Three independent genetic profiles based on mucin expression in early differentiated-type gastric cancers--a new concept of genetic carcinogenesis of early differentiated-type adenocarcinomas |
| Q80554209 | [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology] |
| Q50091796 | [Nuclear Her2 expression in hepatocytes in liver disease]. |
Search more.